Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions
The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.
The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.
What's Your Reaction?
